• Ines Sanches, Cláudia Lares Dos Santos, Ana Figueiredo, and Fernando Barata.
• Chest. 2014 Mar 1;145(3 Suppl):325A.

Session TitleLung Cancer Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Malignant pleural mesothelioma (PM) is a rare tumor, with a 1.2/100.000/year incidence in Portugal. It is related to environment and professional exposure to asbestos, with a latency period varying between 20 and 30 years. It is a locally aggressive advanced tumor associated with bad prognosis. Aims: Describe demographic data, environmental exposure, histological and therapeutic aspects and survival rates of malignant PM in stage III and IV.MethodsRetrospective study of patients with malignant pleural mesothelioma diagnosis in a period of 10 years. Survival analysis was performed using Kaplan Meier method and Cox regression.Results35 patients included, of which 91.5% at stage III and IV; 84.4% male, mean age 65.5±10.2 years. Environmental exposure to asbestos was reported in 56.3%, with a mean duration of 41.4±10.8 years. Diagnosis was obtained performing video-asssited thoracic surgery (87.5%) and blind pleural biopsy (12,5%), with epithelioid (84,4%) being the predominant histological type. All patients received chemotherapy and poli-chemotherapy with Carboplatin and Gemcitabin (53.1%) was more frequent used; 75.0% patients did prophylactic radiotherapy. Secundary effects occurred in 31.3% with hematologic predominance. Median survival was 51.6 ± 9.4 weeks. There was no statistically significant difference according to chemotherapy regimen.ConclusionsMalignant PM should be considered, particularly in men involved in mechanics, even with unrecognized or remote exposure to asbestos. In our series, no difference was observed combining platinum analogs with gemcitabine or pemetrexed.Clinical ImplicationsMalignant PM should be considered, particularly in men involved in mechanics, even with unrecognized or remote exposure to asbestos.DisclosureThe following authors have nothing to disclose: Ines Sanches, Cláudia Lares dos Santos, Ana Figueiredo, Fernando BarataNo Product/Research Disclosure Information.

17 keywords...

hide…